Molecular Dynamics Validation of Crizotinib Resistance to ALK Mutations (L1196M and G1269A) and Identification of Specific Inhibitors
| Autor: | N. Nagasundaram, Rajesh Kannan Rajaretinam, Carlton Ranjith Wilson Alphonse, Prakash Vincent Samuel Gnana |
|---|---|
| Rok vydání: | 2017 |
| Předmět: |
0301 basic medicine
Lung Neoplasms Pyridines medicine.drug_class Mutation Missense Drug resistance Molecular Dynamics Simulation Pharmacology medicine.disease_cause Biochemistry 03 medical and health sciences 0302 clinical medicine Crizotinib Carcinoma Non-Small-Cell Lung hemic and lymphatic diseases Humans Medicine Anaplastic lymphoma kinase Anaplastic Lymphoma Kinase Lung cancer Protein Kinase Inhibitors Molecular Biology Mutation Ceritinib business.industry Receptor Protein-Tyrosine Kinases Cell Biology medicine.disease ALK inhibitor 030104 developmental biology Amino Acid Substitution Drug Resistance Neoplasm 030220 oncology & carcinogenesis Cancer research Pyrazoles business Tyrosine kinase medicine.drug |
| Zdroj: | Journal of Cellular Biochemistry. 118:3462-3471 |
| ISSN: | 1097-4644 0730-2312 |
| DOI: | 10.1002/jcb.26004 |
| Popis: | Anaplastic lymphoma kinase (ALK) positive non-small cell lung cancer (NSCLC) patients are mostly treated with ALK tyrosine kinase inhibitors (TKIs). Crizotinib is the first generation ALK inhibitor practiced as a primary chemo to combat cancer cells followed by second generation inhibitor ceritinib which are effective against crizotinib resistant ALK mutations. However, patients treated with these drugs invariably relapsed because of the development of new drug resistance mutations. In this study we explored the crizotinib resistance in the presence of ALK mutations L1196M and G1269A through molecular dynamics simulation studies. Further mutation specific inhibitors CID 71748211 and CID 71728095 were identified to potentially inhibit ALK with mutations L1196M and G1269A, respectively. This computational investigation in-sighted the molecular factors involved in crizotinib resistance which enhanced in the identification of new ALK drugs that brings individualized medicine to treat ALK positive NSCLC patients with specific mutations. J. Cell. Biochem. 118: 3462-3471, 2017. © 2017 Wiley Periodicals, Inc. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Plný text